New Delhi, May 25 (PTI) Glenmark Pharmaceuticals today said it has entered into a agreement with Triax and Astellas to resolve a patent infringement case in the US over its generic hydrocortisone butyrate cream, used for the treatment of skin infections.
"Glenmark Pharmaceuticals and Glenmark Generics Inc, USA, have entered into a settlement and licence agreement with Triax Pharmaceuticals, LLC, and Astellas Pharma Europe BV and Astellas Pharma International BV to resolve a United States patent infringement suit...," the company said in a filing to the Bombay Stock Exchange.
The suit is related to Glenmark's filing of an abbreviated new drug application (ANDA) for 0.1 per cent hydrocortisone butyrate cream, it added.
Hydrocortisone butyrate cream is a generic version of Triax's Locoid Lipocream.
Under the settlement and licence pact, "Glenmark will be permitted to market and distribute its 0.